Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961476 | 0.96 | SLC10A2 (0.59) | SLC10A2 | |
| SCHEMBL1360860 | 0.94 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL9961458 | 0.94 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL1360858 | 0.94 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL1360861 | 0.94 | SLC10A2 (0.77) | SLC10A2 | |
| SCHEMBL9961482 | 0.93 | SLC10A2 (0.61) | SLC10A2 | |
| SCHEMBL1388853 | 0.93 | SLC10A2 (0.61) | SLC10A2 | |
| SCHEMBL13320299 | 0.93 | SLC10A2 (0.61) | SLC10A2 | |
| SCHEMBL1388934 | 0.89 | SLC10A2 (0.69) | SLC10A2 | |
| SCHEMBL8379990 | 0.86 | SLC10A2 (0.86) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2020-03-05 | — | — | US | disclosed |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. | 2014-09-18 | — | — | US | disclosed |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20220160726-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.